Latest Filings

Issuer Activity

Overview :: Seattle Genetics, Inc. (OQ:SGEN) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for SGEN
USD 38.84 +0.27 (+0.70%)
NSQ Delayed 15 minutes
Apr 17 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
40.24 55.99 N/A 1,319,190 4,781.57
1-Day Low 52-Week Low Yield Avg. Volume  
38.00 28.15 0.0% 1,323,526  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for SGEN within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 12:17am ET April 19th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 7/14 Apr 3/14 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -5,600  
Apr 7/14 Apr 3/14 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -5,600 $43.34
Apr 7/14 Apr 3/14 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 5,600 $5.92
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -5,600  
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,718  
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -5,600 $52.89
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 5,600 $5.92
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -3,718 $52.89
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 3,718 $5.63
Mar 7/14 Mar 3/14 Boerner Christopher S. Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 10,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for SGEN within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 12:17am ET April 19th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 7/14 Apr 3/14 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -5,600  
Apr 7/14 Apr 3/14 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -5,600 $43.34
Apr 7/14 Apr 3/14 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 5,600 $5.92
Mar 7/14 Mar 3/14 Boerner Christopher S. Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 10,000  
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -5,600  
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Non-Qualified Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,718  
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -5,600 $52.89
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 5,600 $5.92
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock S - Open market or private sale -3,718 $52.89
Mar 7/14 Mar 5/14 Siegall Clay B Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 3,718 $5.63
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Clay B. Siegall
Chairman of the Board, President, Chief Executive Officer
Todd E. Simpson
Chief Financial Officer
Eric L. Dobmeier
Chief Operating Officer, Corporate Secretary
Christopher S. Boerner
Executive Vice President - Commercial
Jonathan Drachman
Chief Medical Officer and Executive Vice President, Research and Development
Vaughn B. Himes
Executive Vice President - Technical Operations, Process Sciences
Kirk Schumacher
Senior Vice President - Legal Affairs and Compliance, General Counsel
Charles R. Romp
Senior Vice President - Sales
Eric Sievers
Senior Vice President - Clinical Development
Company Contact
Address: 21823 30TH DRIVE SE
BOTHELL WA 98021
Tel: 1-425-5274160
Website: www.seattlegenetics.com
IR: investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-IRHome
Business Overview
Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.
Financial Overview
For the fiscal year ended 31 December 2013, Seattle Genetics, Inc. revenues increased 28% to $269.3M. Net loss increased 16% to $62.5M. Revenues reflect Collaboration and license agreement reve increase of 58% to $106.8M, Royalty revenues increase from $5.1M to $17.8M, Net product sales increase of 5% to $144.7M. Higher net loss reflects Research and Development increase of 28% to $218.6M (expense), Selling.
Employees: 582 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $4,407M as of Dec 31, 2013
Annual revenue (TTM): $269.26M as of Dec 31, 2013
EBITDA (TTM): -$54.25M as of Dec 31, 2013
Net annual income (TTM): -$62.52M as of Dec 31, 2013
Free cash flow (TTM): -$23.26M as of Dec 31, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 123,109,392 as of Mar 21, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
Incyte (OQ:INCY)
United Therapeutics (OQ:UTHR)